CORONA Remedies Limited has released the transcript of its Earnings Conference Call held on January 05, 2026. The call covered the financial results for the second quarter and half-year ended September 30, 2025. During the call, the management highlighted the company's performance, strategic initiatives, and future outlook.

The company discussed its core philosophy of 'Triple C' – Culture, Courage, and Commitment – which has guided its growth over 21 years. CORONA Remedies, established in 2004, focuses on the Indian pharmaceutical market, with approximately 96% of its revenue from India. Its key therapeutic areas include women's healthcare, cardio-metabolic, pain management, and urology.

Key developments mentioned include the acquisition of seven brand trademarks from Bayer Zydus Pharma in July 2025, which will allow CORONA to enter the ₹1500 crore anti-platelet market with the Noklot and Noklot CV brands, and strengthen its presence in infertility and women's healthcare. The company also highlighted its diversified product portfolio of over 70 brands and its consistent outperformance of the Indian pharmaceutical market.

CORONA operates two WHO GMP-certified manufacturing facilities in Gujarat and Himachal Pradesh, with the Gujarat facility also being EU GMP certified. The company has a total installed annual capacity of 1.65 billion tablets or capsules. It also has two R&D centers approved by the Department of Scientific and Industrial Research.

Financially, for Q2 FY26, revenue stood at ₹361.1 crore, a 15.1% year-on-year growth, with EBITDA at ₹78.5 crore (up 17.4%) and Profit After Tax at ₹52.3 crore (up 21.8%). For H1 FY26, revenue was ₹707.7 crore (up 17% YoY), EBITDA was ₹148.3 crore (up 27.4%), and Profit After Tax was ₹98.5 crore (up 35.1% YoY).

The management expressed confidence in achieving 15% CAGR revenue growth and 20% PAT or EPS growth for the next three to four years. They also discussed strategic expansion into new therapeutic areas such as infertility, nephrology, CNS, oncology, and dermatology, and plans to grow its international business by focusing on complex generic female hormonal products.